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Abstract
Background: The activation of GABAB receptors in the ventral tegmental area (VTA) has been
suggested to attenuate the rewarding properties of psychostimulants, including nicotine. However,
the neurochemical mechanism that underlie this effect remains unknown. Since GABAB receptors
modulate the release of several neurotransmitters in the mammalian brain, we have characterised
the effect of the GABAB receptor agonist baclofen on the release of [3H]-dopamine ([3H]-DA) from
VTA slices of naïve rats and of rats pre-treated with nicotine.
Results: In naïve rats, baclofen concentration-dependently inhibited the electrically evoked release
of [3H]-DA from the isolated VTA (EC50 = 0.103 µM, 95% CI = 0.043–0.249), without affecting the
basal [3H]-monoamine overflow. This effect was mediated by activation of GABAB receptors as it
was blocked by the selective receptor antagonist CGP55845A. Chronic administration of nicotine
(0.4 mg kg-1, s.c., for 14 days) affected neither the basal nor the electrically evoked release of [3H]-
DA from VTA slices. However, the inhibitory effect of baclofen (10 µM) on the stimulated [3H]-
monoamine overflow was abolished in rats pre-treated with nicotine as compared to saline-
injected controls.
Conclusions: Our results demonstrate that GABAB receptor activation reduces the release of DA
from the rat VTA. In addition, a reduced sensitivity of VTA GABAB receptors appears to develop
after chronic exposure to nicotine. The resulting disinhibition of VTA DA neurones might
therefore contribute to the sensitised dopaminergic responses observed in the rat
mesocorticolimbic system following repeated administration of nicotine.
Background
The ventral tegmental area (VTA) represents the site of ori-
gin of the mesocorticolimbic dopaminergic pathway that
has been implicated in mediating the reinforcing proper-
ties of drugs of abuse, including nicotine [1-3].
The majority of cells within the ventral tegmental area
consist of dopaminergic, tyrosine-hydroxylase containing
neurones, which send axon projections to forebrain struc-
tures such as the nucleus accumbens and the prefrontal
cortex. The non-tyrosine hydroxylase containing neu-
rones are mainly GABAergic and function either as local
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interneurones to modulate the activity of the principal
dopaminergic cells or as projection neurones providing
inhibitory input to the cortex and the nucleus accumbens
[4-8].
In addition to classical release from the axon terminals
located in the forebrain, midbrain dopaminergic neu-
rones release dopamine (DA) from their soma and den-
drites [9-12]. The somatodendritic release of DA provides
a primary modulation of dopamine cell function. Activa-
tion of D2 autoreceptors inhibits excitability and firing
rate of VTA dopaminergic neurones [13,14] and decreases
the release of dopamine from their axon terminals in the
forebrain [15,16]. Furthermore, somatodendritic
dopamine can indirectly modulate the activity of mid-
brain dopamine cells by acting on D1 receptors, which are
found on GABA- and excitatory amino acids-containing
terminals in the VTA [17-20].
Besides the short-loop feedback inhibition exerted by
dopamine, the activity of VTA dopaminergic neurones is
strongly modulated by glutamatergic and GABAergic
inputs. Activation of NMDA receptors by excitatory affer-
ents arising from the medial prefrontal cortex [21,22]
induces burst firing in VTA DA neurones [23-25], which is
associated with increased dopamine release from the
nerve terminals in the nucleus accumbens [26,27]. The
VTA also receives an extensive inhibitory influence arising
from GABA interneurones and descending projections
from the basal forebrain, innervating GABAA and GABAB
receptors, respectively [4]. Activation of GABAB receptors
has been reported to inhibit the spontaneous pacemaker-
like activity of VTA DA neurones in slice preparations
[4,28,29] and to decrease the firing rate and burst firing of
these cells in vivo [30,31].
Photomicrograph of a representative coronal section of rat brain labelled with a polyclonal antibody directed against tyrosine  hydroxylase Figure 1
Photomicrograph of a representative coronal section of rat brain labelled with a polyclonal antibody directed against tyrosine 
hydroxylase. The picture shows the orientation of the cuts (dark lines) for the dissection of the ventral tegmental area (VTA). 
The basal cerebral peduncle (Cp) was used as a visual landmark to obtain the coronal section containing the VTA. To remove 
the substantia nigra (pars compacta, SNC, and reticulata, SNR) from this slice, two transversal cuts were made along the 
medial lemniscus (Ml) on either side. Finally, the VTA was dissected out by making a horizontal cut 1.5 mm dorsal to the ven-
tral edge of the section and stripped of the interpeduncular nucleus (IP) by cutting 0.5 mm above the same edge. Scale bar is 1 
mm.
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In addition, in vivo microdialysis studies have demon-
strated that intra-VTA administration of the GABAB recep-
tor agonist baclofen decreases extracellular dopamine
levels in both the somatodendritic [32,33] and the axon-
terminal regions of the mesocorticolimbic system [15,16].
The GABAB receptor-mediated inhibition of the activity of
the mesocorticolimbic neurones might explain the effec-
tiveness of baclofen to suppress nicotine self-administra-
tion when microinjected into the VTA [34]. In fact, the
rewarding properties of nicotine have been ascribed to its
ability to stimulate VTA dopamine neurones that project
to the nucleus accumbens [2,35]. Acute administration of
nicotine to drug-naïve rats increases extracellular levels of
dopamine in the nucleus accumbens shell, while repeated
exposure to the drug results in sensitisation of its effect on
dopamine overflow in the nucleus accumbens core [36].
Sensitisation of the mesoaccumbens dopamine response
to nicotine appears to be closely related to the depend-
ence-liability of the drug and has been suggested to reflect
an altered control of DA release, including reduced inhib-
itory influence by DA autoreceptors, and co-stimulation
of NMDA receptors [37-39].
Since GABAB receptors have a prominent role in regulating
the activity of VTA DA neurones and they appear to be
involved in the modulation of nicotine reinforcing prop-
erties, we have characterised the effect GABAB receptor
stimulation on the somatodendritic release of [3H]-DA
from VTA slices of naïve rats and used this model to deter-
mine whether chronic exposure to nicotine results in
altered GABAB receptor-mediated modulation of VTA DA
cells.
Results
Tetrodotoxin and calcium dependence of the stimulated 
[3H]-DA release from VTA slices
The influence of tetrodotoxin (TTX) and calcium on the
electrically evoked release of [3H]-DA from ventral teg-
mental slices of naïve rats was evaluated in order to deter-
mine its physiological significance under the
experimental conditions used here. Removal of calcium
with the inclusion of EGTA (1 mM), or addition of TTX (1
µM) to the superfusion buffer abolished the stimulated
release of [3H]-DA from the tissue, without significantly
affecting the spontaneous monoamine overflow. Recov-
ery of the release occurred during the second stimulation
(S2), after removal of TTX or replacement of calcium to
the superfusion buffer (Figure 2).
Effect of GABAB receptor activation on VTA [3H]-DA 
release
Baclofen (0.1–100 µM), added to the superfusion buffer
36 min before the second stimulation, dose-dependently
reduced the electrically evoked [3H]-DA release from VTA
slices (EC50 = 0.103 µM, 95% CI = 0.043–0.249, n = 4–7
rats, Figure 3), without having any significant effect on the
basal monoamine overflow (data not shown).
The inhibitory effect of baclofen (10 µM) on the release of
[3H]-DA was abolished when the selective GABAB receptor
antagonist CGP55845A (1 µM), which had no effect on its
own, was added to the superfusion buffer concomitantly
with baclofen (Figure 4). Release of dopamine, expressed
as S2/S1 ratio, was 1.09 ± 0.10 for control slices perfused
with buffer alone; 0.73 ± 0.08 for baclofen added before
S2 (P < 0.05 vs control, one-way ANOVA, Dunnet's post
hoc test, n = 6–10 rats); 0.99 ± 0.13 for CGP55845A alone;
and 0.93 ± 0.14 for slices perfused with both baclofen and
CGP55845A.
Effect of nicotine pre-treatment on the release of [3H]-DA 
from VTA
The release of [3H]-DA from the VTA slices of rats that
received a chronic nicotine treatment was compared with
the overflow observed in saline-control animals. Neither
the basal nor the electrically stimulated release of [3H]-DA
was significantly affected by the drug pre-treatment (Fig-
ure 5).
Calcium-dependence and tetrodotoxin (TTX) sensitivity of  the electrically evoked release of [3H]-DA from ventral teg- mental area slices Figure 2
Calcium-dependence and tetrodotoxin (TTX) sensitivity of 
the electrically evoked release of [3H]-DA from ventral teg-
mental area slices. Electrical stimulation (20 mA, 2 Hz, 4 min) 
occurred 14 min (S1) and 59 min (S2) after the beginning of 
sample collection. Slices were perfused with buffer alone 
(control), calcium-free medium containing 1 mM EGTA 
(Ca2+-free), or buffer containing 1 µM TTX for 15 min before 
and during S1 (black bar). After 18 min from the beginning of 
sample collection, all samples were superfused with normal 
buffer. Values represent mean ± s.e.mean (n = 3 rats).
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Effect of baclofen on the release of [3H]-DA from VTA of 
nicotine-treated rats
The effect of baclofen on the VTA [3H]-DA release in rats
pre-treated with nicotine was assessed and compared with
the effect of the drug in saline-control animals (Figure 6).
The addition of baclofen (10 µM) to the superfusion
buffer for 36 min before and during S2, significantly
reduced the evoked release of [3H]-DA from VTA slices of
rats pre-treated with saline (S2/S1: control, 1.06 ± 0.08;
baclofen, 0.73 ± 0.06; P < 0.01, ANOVA for repeated
measures, Bonferroni post-test, n = 5 rats). By contrast, in
the rats pre-treated with nicotine, the addition of baclofen
to the superfusion buffer did not produce any significant
effect on the evoked release of [3H]-DA (S2/S1: control,
1.02 ± 0.06; baclofen, 0.92 ± 0.05) (Figure 6).
Discussion
In the present study we have characterised the effect of
baclofen on the release of [3H]-DA from ventral tegmental
area slices of naïve rats, and used this model for studying
the functional status of local GABAB  receptors after
chronic exposure to nicotine.
Baclofen-mediated inhibition of the electrically evoked [3H]- DA release from ventral tegmental area slices of naïve rats  (EC50 = 0.103 µM, 95% CI = 0.043–0.249) Figure 3
Baclofen-mediated inhibition of the electrically evoked [3H]-
DA release from ventral tegmental area slices of naïve rats 
(EC50 = 0.103 µM, 95% CI = 0.043–0.249). Baclofen (0.01–
100 µM) was added to the superfusion buffer 36 min before 
and during S2. Values represent mean ± s.e.mean (n = 4–7 
rats).
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Reversal of baclofen-mediated inhibition of the evoked [3H]- DA release from VTA slices by the GABAB antagonist  CGP55845A Figure 4
Reversal of baclofen-mediated inhibition of the evoked [3H]-
DA release from VTA slices by the GABAB antagonist 
CGP55845A. Baclofen (Bacl, 10 µM) and/or CGP55845A 
(CGP, 1 µM) were added to the superfusion buffer 36 min 
before and during S2. Drug effects were assessed by compar-
ing the ratio S2/S1 in the presence and absence of the drug, 
respectively. Values represent mean ± s.e.mean (n = 6–10 
rats). *p < 0.05 vs control (one-way ANOVA, Dunnett's post 
hoc test).
Effect of nicotine pre-treatment on basal and electrically  evoked release of [3H]-DA from VTA slices Figure 5
Effect of nicotine pre-treatment on basal and electrically 
evoked release of [3H]-DA from VTA slices. The rats 
received daily subcutaneous injections of nicotine (0.4 mg kg-
1, n = 6) or saline (n = 6) for 14 consecutive days and the 
experiments were performed 24 hours after the last injec-
tion. An electrical stimulation (20 mA, 2 Hz, 4 min, black bar) 
was applied to the VTA slices 14 min after the beginning of 
sample collection. The data are expressed as fractional [3H]-
DA release and represented as mean ± s.e.mean.
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The electrically induced [3H]-DA release from VTA soma-
todendrites was calcium-dependent and tetrodotoxin-sen-
sitive. This suggests that the release is tightly coupled with
voltage-sensitive calcium influx and that it depends on the
propagation of action potentials by voltage-dependent
sodium channels. Our findings are consistent with the cal-
cium sensitivity and the partial block by tetrodotoxin of
the release of endogenous dopamine observed in DA cell
body areas using microdialysis [10,40]. They are also con-
sistent with the calcium and tetrodotoxin dependency of
the electrically evoked [3H]-DA release from slices of the
ventral tegmentum [41]. Therefore, under the experimen-
tal conditions used in the present study, release of
preloaded [3H]-dopamine appears to be of neuronal ori-
gin and to have physiological relevance.
Although the radioactivity measured in the collected efflu-
ent may consist of a mixture of neurotransmitters and
metabolites, the amount of tritium released from rat brain
slices after electrical stimulation has been previously
shown to represent a close estimation of the release of
labelled or endogenous DA release [42,43]. Furthermore,
the release of metabolites during the superfusion was
inhibited by the presence of the monoamine oxidase
inhibitor pargyline in the superfusion buffer [44]. There-
fore, under our experimental conditions, the overflow of
tritium from VTA slices seems likely to represent, predom-
inantly, [3H]-DA and closely resembles exocytotic release
of DA, as it was dependent on the presence of calcium in
the superfusion buffer.
The VTA receives GABAergic input from both interneu-
rones and descending projections from the basal fore-
brain, innervating GABAA  and GABAB  receptors,
respectively [4,45]. Activation of GABAB receptors, located
both postsynaptically on dopaminergic neurones and pre-
synaptically on glutamatergic nerve terminals [29],
decreases the spontaneous pacemaker-like activity and the
burst firing of VTA DA cells [4,31]. In addition, baclofen
microinjected into the VTA has been shown to decrease
somatodendritic release of dopamine in this midbrain
region as monitored by in vivo microdialysis [32,33]. The
activation of GABAB receptors has also been reported to
inhibit the potassium- or electrically evoked release of
dopamine from various regions of the mammalian brain
in vitro [46,47]. However, to date, there is a lack of infor-
mation regarding the effect of GABAB receptor activation
on the release of somatodendritic dopamine from the iso-
lated VTA. Therefore, in the present study we have demon-
strated that baclofen dose-dependently reduces the
electrically evoked release of [3H]-DA from ventral teg-
mental area slices of naïve rats. This effect appears to be
mediated by activation of GABAB receptors, since it was
abolished by superfusion of the tissue with the selective
receptor antagonist CGP55845A [48].
The existence of a tonic GABAB receptor-mediated inhibi-
tion of somatodendritic DA release has been suggested by
the evidence that, in vivo, the administration of
CGP55845A into the ventral tegmental area produces a
dose-dependent increase in VTA dopamine levels [49]. By
contrast, our results demonstrate that the GABAB receptor
antagonist CGP55845A does not have any significant
effect on the release of [3H]-DA when applied on its own
to the VTA slices. The apparent discrepancy between the
two studies may be ascribed to the fact that we have used
isolated tissue, which is deprived of the tonic GABA input
arising from the forebrain, whereas in the work of
Giorgetti et al. [49] the long-loop projections to the VTA
are indeed intact. In fact, the innervation of VTA GABAB
receptors originates primarily from projection neurones
located in the nucleus accumbens and the ventral palli-
dum, while the GABA interneurones appear to innervate
mainly GABAA receptors [4,50].
Interestingly, previous neurochemical studies have shown
that activation of GABAB receptors in the ventral tegmen-
tal area of naïve rats inhibits the release of dopamine not
only in the cell body area, but also in mesocorticolimbic
terminal regions, such as the nucleus accumbens [33] and
Effect of baclofen on the electrically evoked release of [3H]- DA from VTA slices of rats pretreated with nicotine or  saline Figure 6
Effect of baclofen on the electrically evoked release of [3H]-
DA from VTA slices of rats pretreated with nicotine or 
saline. The rats received daily subcutaneous injections of nic-
otine (0.4 mg kg-1, n = 5) or saline (n = 5) for 14 consecutive 
days and the experiments were performed 24 hours after the 
last injection. Two electrical stimulations (20 mA, 2 Hz, 4 
min) were applied to the slices 14 min (S1) and 59 min (S2) 
after the beginning of sample collection. Baclofen (10 µM) 
was added to the superfusion buffer 36 min before and dur-
ing S2. Control tissue was perfused with buffer alone during 
both S1 and S2. Data are expressed as mean ± s.e.mean and 
compared by ANOVA for repeated measures. **p < 0.01 vs 
saline-control (Bonferroni post-test).
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the prefrontal cortex [15]. The reduction of mesocorticol-
imbic dopamine release might represent a likely mecha-
nism by which baclofen attenuates nicotine self-
administration in rats when microinjected into the ventral
tegmental area [34]. However, to date, this hypothesis has
not been confirmed and little information is known about
the neurochemical mechanisms underlying the GABAB
receptor-mediated modulation of nicotine reinforcement,
as well as about the pharmacological interaction between
nicotine and GABAB receptors. With the present study we
demonstrate that while baclofen significantly reduces the
electrically induced release of [3H]-DA from the VTA of
saline-control rats, it has no effect on the evoked
monoamine release from VTA slices of nicotine pre-
treated rats. This finding represents the first demonstra-
tion that chronic exposure to nicotine might result in
reduced GABAB-mediated inhibition of VTA dopaminer-
gic neurones. This hypothesis is also consistent with pre-
liminary  in vivo studies performed in our laboratory
showing that, after chronic pre-treatment of the rats with
nicotine, microinfusions of baclofen into the VTA failed
to reduce both the spontaneous and the nicotine-evoked
overflow of dopamine in this midbrain region (D. Aman-
tea, unpublished observation). Taken together, our find-
ings suggest that after chronic nicotine the GABAB receptor
may be desensitised, and this would result in a reduced
inhibitory control of VTA dopaminergic cells, thereby
facilitating a more sustained increase in the responses of
mesolimbic neurones to nicotine. Interestingly, the inhib-
itory action of baclofen on VTA DA cells may be
accounted for by stimulation of GABAB receptors located
on dopaminergic and/or glutamatergic neurones [28,29].
This suggests that the effect observed after chronic admin-
istration of nicotine may be ascribed to a reduced sensitiv-
ity of GABAB receptors located either on DA cell bodies or,
presynaptically, on glutamatergic terminals impinging
onto DA neurones. The latter hypothesis would lead to
the speculation that a chronic treatment with nicotine
might result in increased excitatory input to the VTA, due
to a reduced GABAB-mediated inhibitory control.
Therefore, disinhibition or increased excitatory input to
midbrain DA cells might contribute to the augmented
dopamine output observed in the nucleus accumbens
after a challenge injection of nicotine in rats pretreated
with the drug [36,37]. Desensitisation of GABAB receptors
located in the VTA has also been reported to occur after
chronic cocaine administration, as the drug treatment
resulted in reduced functional coupling of the receptor to
G-proteins [51]. However, we have previously demon-
strated that GABAB receptor expression and coupling to G-
proteins in the ventral tegmental area of the rat are not
altered after chronic exposure to nicotine [52], suggesting
that desensitisation might occur at other levels, perhaps
on downstream effector mechanisms. Nevertheless, it can-
not be ignored that the use of in vitro autoradiography did
not allow us to discriminate between receptor subpopula-
tions, including receptor subtypes involved in different
functions. Thus, if the GABAB receptors directly implicated
in the control of dopamine release from the VTA represent
only a small fraction of the overall receptor population in
this area, autoradiographic analysis would not be
sufficiently sensitive to evaluate receptor modifications
occurring after chronic exposure to nicotine. Further stud-
ies aimed at characterising the mechanisms involved in
GABAB receptor desensitisation following chronic nico-
tine treatment are required to clarify this issue.
Not surprisingly, basal and evoked release of dopamine
from VTA slices of rats chronically injected with nicotine
did not differ from release obtained from saline-control
tissue. This confirms that sensitised dopaminergic
responses to the drug depend on the activation of nico-
tinic receptors (nAChRs) and are not the result of a generic
increase in neuronal activity. Similar results have been
obtained in striatal synaptosomes from rats pretreated
with the nAChR agonist anatoxin-a for 7 days: while the
drug pre-exposure increased the nicotine-stimulated
release of [3H]-DA from the in vitro preparation, no differ-
ence was found in the K+-evoked release between the drug
pretreated animals and the saline-injected controls [53].
Thus, although the electrical stimulation used in the
present study does not provide information about desen-
sitisation or up-regulation of nAChRs, it nevertheless
served as a reliable model to study the functional status of
the GABAB receptor in the ventral tegmental area of rats
pretreated with nicotine.
Conclusions
In conclusion, we have demonstrated that activation of
GABAB receptors inhibits the release of preloaded [3H]-DA
from somatodendritic fields of VTA neurones in naïve
rats. This effect appears to be reduced in rats chronically
treated with nicotine, suggesting that subsensitivity of
GABAB receptors in the VTA might occur as a result of the
drug treatment. This, in turn, would lead to disinhibition
of VTA dopaminergic cells, which might contribute to the
increased activity of mesocorticolimbic neurones follow-
ing repeated exposure to nicotine.
Methods
Drugs
[3H]-Dopamine (specific activity 47 Ci/mmol) was
obtained from Amersham (Buckinghamshire, UK). (-)-
Baclofen (CGP11973A) and CGP55845A were generous
gifts from Novartis Pharma (Basel, Switzerland). (-)-Nico-
tine hydrogen tartrate salt, nomifensine, pargyline, tetro-
dotoxin and ethylene glycol-bis (b-amino ethyl ether)
tetraacetic acid (EGTA) were purchased from Sigma-
Aldrich (Dorset, UK). All the other chemicals used in thisBMC Pharmacology 2004, 4:24 http://www.biomedcentral.com/1471-2210/4/24
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study were obtained from Fisher Scientific (Leicestershire,
UK).
Subjects
Male Wistar rats (weight 250–280 g) were maintained on
a 12-h light/dark schedule (on 6:00–18:00), with free
access to food and water.
For the drug treatments, rats, initially weighing 150–180
g, received subcutaneous injections of nicotine (0.4 mg
kg-1, expressed as free-base) or vehicle (0.9% NaCl, 1 ml
kg-1) for 14 consecutive days, once a day, between 9:30
and 10:30 a.m. Experiments were performed 24 hours
after the last injection. All procedures were carried out in
accordance to the UK Animals (Scientific Procedures) Act,
1986.
Tissue preparation
Animals were sacrificed by stunning followed by decapita-
tion. The brains were rapidly removed from the skull and
cooled for 2–3 min in ice-cold superfusion buffer of the
following composition (in mM): NaCl, 118; KCl, 4.7;
CaCl2, 1.3; MgCl2, 1.2; NaH2PO4, 1; NaHCO3, 25; glu-
cose, 11.1; Na2EDTA, 0.004 and ascorbic acid, 0.3 (pH
7.4), saturated with 95% O2/5% CO2.
Each brain was dissected according to visual anatomical
landmarks and the atlas of Paxinos & Watson [54]. To
obtain the coronal section containing the VTA, the brain
was placed ventral side up and two parallel cuts were
made at the level of the mammillary body and the medial
interpeduncular nucleus (approximately 5–6 mm poste-
rior to bregma), using as landmark the basal cerebral
peduncle. Two transversal cuts were made in correspond-
ence of the medial lemniscus, to remove the substantia
nigra from the slice. Finally the ventral part of the section
was dissected out by making a horizontal cut 1.5 mm dor-
sal to the ventral edge of the section and deprived of the
interpeduncular and mammillary nuclei by cutting 0.5
mm above the same edge. The procedure used for the
dissection of the VTA is illustrated in Figure 1, which
shows a photomicrogaph of a representative coronal slice
immunohistochemically stained for tyrosine hydroxylase.
The dissected VTA was cross-chopped (250 µm × 250 µm)
with a McIlwain tissue chopper and the tissue slices were
washed and resuspended in ice-cold superfusion buffer.
Tissue superfusion
The VTA slices were pre-incubated in oxygenated super-
fusion medium at 37°C for 15 min, followed by incuba-
tion with 0.1 µM [3H]-DA for 30 min, in the dark and in
the presence of 10 µM pargyline. The incubation was
terminated by washing the slices three times with buffer
containing 2.5 µM nomifensine.
150 µl aliquots of slice suspension (1.5 to 2.0 mg of tis-
sue) were transferred to each chamber of a Brandel 2000
superfusion apparatus. The tissue was superfused at a rate
of 0.5 ml min-1 with oxygenated buffer maintained at
35°C and containing 2.5 µM nomifensine, to block
dopamine uptake, and 10 µM pargyline to ensure that
[3H] overflow represented primarily [3H]-DA rather than
its metabolites [44].
After 36-min pre-superfusion, the effluent was collected in
consecutive fractions of 4 min 30 sec each. The release of
[3H]-DA was induced by electrical field stimulation (20
mA, 2 Hz for 4 min) using a Brandel constant current
stimulator. Two stimulations occurred 14 min (S1) and
59 min (S2) after the beginning of sample collection.
Test drugs were added to the superfusion medium 36 min
before the second stimulation. To determine the effects of
calcium and tetrodotoxin (TTX), slices were perfused with
Ca2+-free buffer (in the presence of 1 mM EGTA), or buffer
containing 1 µM TTX, for 15 min before and during S1.
The superfusion medium was then replaced with normal
buffer until the end of superfusion and during the second
stimulation.
Liquid scintillation counting
At the end of the superfusion, the slices with their filters
were removed from the chamber, suspended in 1 ml of
buffer, and sonicated. OptiPhase 'HiSafe' 3 scintillation
fluid (Perkin Elmer, UK) was added to each vial and the
radioactivity content in the superfusion samples and in
the tissue slices was assayed by liquid scintillation count-
ing using a Tri-Carb® 1500 liquid scintillation analyser
(Packard Bioscience Company), programmed to count for
tritium, 3 minutes per vial, at an efficiency of 60%. The
number of disintegrations per minute (d.p.m.) was meas-
ured in order to determine the concentration of tritium in
each sample.
Data analysis
For each time point (4 min 30 sec), release of radioactivity
was expressed as fractional release, i.e., as a percentage of
the amount of radioactivity in the tissue at the beginning
of that collection. The electrically evoked release was
expressed as the mean of the increased fractional release
above baseline in the two fractions after the beginning of
stimulations. Basal release, in turn, was calculated as the
mean of the amount of radioactivity present in the three
samples just before each period of electrical stimulation.
Results were expressed as mean ± s.e.mean of n independ-
ent experiments conducted in either triplicate or quadru-
plicate. For statistical analysis one-way ANOVA with
Dunnett's post hoc test was used to compare values of S2/
S1 in the presence of a drug versus values of S2/S1 fromBMC Pharmacology 2004, 4:24 http://www.biomedcentral.com/1471-2210/4/24
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control slices superfused with buffer alone. When nico-
tine or saline were administered to the animals, values of
S2/S1 were analysed by ANOVA with repeated measures
(with or without baclofen) with pre-treatment as factor
analysed, and post hoc comparisons were made using the
Bonferroni test. The accepted level of significance was p <
0.05.
Histology
Immunohistochemistry was performed on naïve rat brain
during preliminary experiments aimed at characterising
the exact orientation of the cutting for the dissection of
the VTA (Figure 1). Animals were sacrificed by stunning
and decapitation and their brains rapidly removed from
the skull. A coronal section containing the VTA was
obtained as described above and the tissue was post-fixed
in 4% paraformaldehyde (BDH) for 48 hours at 4°C.
Serial coronal sections (30 µm thick) were cut using a
vibratome and washed in 0.01 M phosphate buffered
saline (PBS, Sigma-Aldrich), pH 7.4. Slices were incubated
with 3% hydrogen peroxide (H2O2) for 30 min, followed
by incubation with 0.2% Triton X-100 (Sigma-Aldrich)
for 20 min at room temperature.
After a 1-hour pre-incubation in 10% normal goat serum
(NGS, Vector), the primary antibody (rabbit polyclonal
antibody to tyrosine-hydroxylase, Affiniti) was applied at
a final concentration of 1:1000 (in 0.01 M PBS) and the
sections were allowed to incubate overnight at 4°C. After
three washes with fresh buffer, the slices were incubated
for 90 minutes at room temperature with a biotinylated
secondary goat anti-rabbit antibody (1:200 dilution,
Chemicon).
Immunoreactivity was visualised by the avidin-biotin
complex method of detection (Vectastain Elite ABC Kit,
Vector) using 3,3'diaminobenzidine (DAB, peroxidase
substrate kit, Vector) as the chromogen.
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